Frank E. Thomas - 09 May 2023 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Reporting relationship: Director
Issuer ticker: LRMR
Reported as of: 09 May 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 May 2023, 16:28:50 UTC
Prior SEC filing: 14 Mar 2023
Next SEC filing: 10 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Johansson, Attorney-in-fact

Key filing fact

Frank E. Thomas filed Form 4 for Larimar Therapeutics, Inc. (LRMR) on 11 May 2023.

Key facts

This page summarizes Frank E. Thomas's Form 4 filing for Larimar Therapeutics, Inc. (LRMR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 May 2023, 16:28.

Change

Previous filing in this sequence was filed on 14 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LRMR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +8,300
Change %
Price: $0.000000
Shares after: 8,300
Date: 09 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,300
Exercise price: $5.09
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.